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ABSTRACT 
Recombinant human bone morphogenetic protein-2 (rhBMP-2) is a clinically available 
osteogenic growth factor.  In its current form, approved for clinical use, however, the growth 
factor is delivered in excessively high doses, resulting in unpredictable bone growth and 
unwanted, sometimes life-threatening, clinical side effects.  It has clearly been demonstrated that 
the sustained, long-term release of the proteins can lead to improved ossification, owing 
particularly to the rapid metabolism of the biologically active growth factor when delivered 
alone in solution.  Delivery systems for rhBMP-2 have been investigated extensively; yet still, 
further exploration into the best means of protein delivery — in order to curb the side effect 
profile and improve the quality of the bone generated — is warranted.  The present review of 
literature introduces extensive work evaluating optimal rhBMP-2 delivery, with particular focus 
on natural polymers, inorganic materials, as well as synthetic materials for protein delivery.  In 
particular, poly(DL-lactide-co-glycolide) (PLGA) microspheres, conventionally fabricated by a 
solvent extraction/evaporation procedure, are discussed for their use in sustained drug delivery. 
The application of rhBMP-2 for bone tissue engineering holds great promise for researchers and 
clinicians in both the medical and dental fields; yet, there remains a great need for further 
investigation of improved protein delivery mechanisms. 
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REVIEW OF LITERATURE 
 The treatment of skeletal defects within the craniofacial region poses a significant 
challenge for plastic surgeons, oral and maxillofacial surgeons, and dental professionals alike.  
Such defects can be the result of trauma, disease, or congenital deformities — such as cleft lip 
and palate — and can lead to disfigurement, and loss of ability for normal function.1  Depending 
on defect size, tissue repair is possible; but in defects beyond a critical size, bone grafts are often 
necessary.  Autogenous bone grafts remain the optimal, “gold standard” of treatment; however, 
there is significant post-op pain and donor site morbidity,2, 3 as well as increased costs and 
limited donor site bone availability, leading investigators to seek out alternate graft sources.2  
Bone Morphogenetic Proteins 
 Recombinant human bone morphogenetic proteins (rhBMPs), key cytokines in bone 
formation and repair, have been evaluated for their use in the treatment of craniofacial defects.2, 4, 
5  Bone tissue engineering involves the delivery of an osteoinductive growth factor—such as 
BMP—at the site of the defect.  BMP-2, BMP-4, BMP-7, and BMP-9 are members of the 
transforming growth factor beta (TGF-β) superfamily, and have demonstrated the capacity to 
induce progenitor cells from mesenchymal sources to differentiate into osteoblasts.4  They play a 
role in osteogenesis, chondrogenesis, angiogenesis, as well as mesenchymal stem cell 
chemotaxis.4, 6 
 BMPs play a critical role in cellular functioning and the formation of new tissues; 
however, the most effective means of delivering the growth factor to the site of repair has yet to 
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be determined.  When administered as a bolus dose, rapid dispersion throughout the body can 
result in undesirable side effects such as local inflammation, soft tissue edema, ectopic or 
heterotopic bone formation, and seromas.7-9  BMPs have a very short half-life; therefore, when 
administered in solution, much of the bioactive protein is rapidly lost, leaving insufficient 
amounts of protein to act at the intended site.10  
Current clinical applications:  
 Currently, the growth factor is approved for clinical use in a few select applications.  In 
the form of the INFUSE bone graft, rhBMP-2 has been approved by the U.S. Food and Drug 
Administration as a medical device for use in spinal fusions, sinus lift procedures, and repair of 
alveolar defects after dental extractions.11  Approval for the clinical delivery of rhBMP-2 with 
INFUSE was first granted by the FDA in 2002, for delivery of the growth factor in an adsorbable 
bovine type I collagen sponge (ACS).11  There are, however, drawbacks of this application; the 
most striking of which is the extreme, supraphysiologic dose of protein required for the desired 
osteogenic effect.12, 13  It is noted that the amount of rhBMP-2 present in one INFUSE dose for a 
single spinal fusion exceeds the amount of exogenous BMP naturally present in 1000 humans.13  
Nonetheless, rhBMP-2 is still combined with adsorbable collagen sponges for clinical use.   
 A retrospective cohort study from the Journal of the American Medical Association 
evaluated 328,468 patients undergoing spinal fusion procedures between 2002 and 2006.14  They 
reported an extreme increase in the use of the growth factor from 0.69% to 24.89% during the 
four year period.  In addition, higher rates of complications such as dysphagia, edema, 
hematoma, and respiratory problems, were reported when BMP was used in anterior cervical 
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fusions.  The use of BMP was also correlated with increased length of hospital stay and higher 
hospital charges.14  The authors were the first to compile national data on the use of BMPs in 
spinal fusion surgery, and successfully highlighted the widespread use of the growth factor 
clinically and the concerns of many medical professionals. 
 In addition, the growth factor is often used off-label in other anatomical sites such as 
alveolar clefts or cranial vault reconstruction.15  Alonso et al.16 compared the delivery of 
rhBMP-2 in an adsorbable collagen sponge matrix to a traditional iliac crest autogenous bone 
graft (ABG) in cleft palate patients aged 8-12 years, all with pre-operative orthodontic maxillary 
expansion.  Results illustrated alveolar bony bridging, as well as normal dental eruption, in all 
patients.  Overall average bone volume was slightly less in the treatment group as compared to 
the ABG patients, but clinical results were favorable in both groups.  The authors noted that the 
decreased structural stability of the collagen sponge carrier was problematic.  Additionally, post-
operative swelling was noted in more than a third of the rhBMP-2 graft group.16  Similar post-
operative swelling was reported by Shah, Smyth, and Woo15 in a case report of an rhBMP-2/ACS 
implant for a cranial vault repair in a 2 year-old boy with craniosynostosis.  The patient exhibited 
severe facial, periorbital, and scalp swelling, resulting in surgical removal of the implant.15  It has 
been suggested that the side effect profile of rhBMP-2 is more extreme and more common after 
such off-label uses.9  Moreover, the adverse side effects associated with the growth factor are of 
extreme concern in a pediatric, growing population.   
 Off-label use of rhBMP-2 is also common in the field of periodontics, where the growth 
factor is delivered in alveolar defect repair, as well as sinus elevation procedures, by combining 
pieces of rhBMP-2-soaked ACSs with particulate allograft or xenograft bone materials.17  Due to 
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the off-label nature of these uses, there are few clinical studies evaluating their efficacy.  A 2012 
study evaluated the use of rhBMP-2/ACS in combination with a bovine-derived xenograft in 
human subjects undergoing sinus elevation procedures.17  The authors illustrated that in samples 
in which rhBMP-2/ACS was delivered in combination with a xenograft, there was increased 
resorption of the graft material, combined with decreased new bone formation, and increased 
marrow spaces noted histologically, compared to patients treated with the xenograft alone.  They 
concluded that the combination of these materials was not efficacious.17  Their findings are in 
contrast with previous work comparing rhBMP-2/ACS with the use of a collagen sponge alone 
for a similar procedure, in which investigators concluded that the combination of rhBMP-2 and  
an ACS was the optimal treatment condition.18  Inconclusive results and limited studies suggest a 
need for further investigation in this arena.   
 In light of the aforementioned bioactivity and side effects, as well as the growth factor’s 
often inconsistent clinical performance, much of the scientific and medical community agree that 
the application of rhBMP-2 for clinical procedures needs further optimization.11  Hence, with a 
particular focus on animal studies, there has been a great deal of investigation evaluating the 
growth factor and its optimal delivery methods.  
BMP delivery: Requirements for delivery systems 
 In vitro studies have demonstrated the efficacy of BMPs in the initiation of osteogenetic 
pathways, as well as subsequent activation and differentiation of mesenchymal cells.4  However, 
in vivo, there are often mixed results; as the protein can be degraded and tissue regeneration is 
inconsistent.19  Several factors effect BMP function in vivo.  The osteoinductive protein must 
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remain at the defect site for time enough to allow for the migration of tissue forming cells to the 
site, and their subsequent proliferation and differentiation.2  The mode of delivery of BMP is 
critical for its action.  Thus, there has been extensive investigation into the optimal delivery 
system and carrier for these proteins to the site of bone regeneration.  
 It is widely agreed that delivery systems for rhBMP-2 should be relatively easy and cost-
effective to manufacture, with the ability to be sterilized for in vivo use.20  The delivery system 
should be reliable and consistent in form, yet also malleable—with the capacity to be shaped to 
fit a wide variety of craniofacial defects.6  They should be porous, allowing the infiltration of 
mesenchymal cells and blood vessels; yet they should also be mechanically stable, with the 
ability to withstand compressive and tensile forces.20  The rate of resorption of the carrier itself 
should aim to mirror the rate of formation of the new bony tissue.  In addition, the rate of 
osseoregeneration should not be effected by inflammatory or foreign material reactions to the 
carrier substance itself.12   
 The biologic action of BMPs can be shaped by their carrier and the manner in which they 
are delivered.  The carrier has the ability to alter the local retention of the protein, the release 
kinetics and mechanism of release, and the overall dose of the protein necessary for 
osteoinduction and bone formation.2   
Site of action: 
 Most critically, the carrier should stabilize the protein, retaining it in place at the site of 
intended bone formation.  If delivered systemically, rhBMP-2 is rapidly cleared from the 
bloodstream; therefore, delivery of BMP directly to the site of desired bone formation, and in a  
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carrier that maintains adequate protein levels, is imperative.2  Early studies illustrated that a 
significantly larger percentage of the delivered dose of BMP is retained at the delivery site when 
the protein is administered in a gelatin or collagen-like substance as compared to in a purely 
soluble form.21  By retaining the protein at the delivery site, the pharmacokinetics of BMPs can 
be altered: Chen and Mooney7 note that delivery methods successful in sequestering growth 
factors at the site of action result in enhanced bone formation and require an overall lower dose 
of the growth factor. 
rhBMP-2 Release kinetics: 
 Much investigation has looked into the optimal release kinetic profile for rhBMP-2; yet 
there does not appear to be a clear consensus as to one particular profile that consistently leads to 
enhanced bone formation.  Studies have indicated that the extremes of protein release are not 
ideal: i.e. bolus delivery or incredibly low level, slow release do not improve results.20  In fact, 
much work has suggested that combining an initial burst release—in order to bring in necessary 
cell mediators and trigger vasculogenesis—with a slower, long-term delivery of the growth 
factor can lead to increased osteogenesis.22 
 Determining an ideal release kinetic profile is further complicated by the fact that in vivo 
factors can alter the functioning the growth factor and its delivery system.  Release kinetics are 
affected by the anatomical site of application.  As Geiger et al.20 suggest, when rhBMP-2 is 
delivered to a less vascularized area, diffusion of the protein away from that area might succeed 
the body’s ability to bring in the cytokines and cells necessary to commence bone formation.  
Thus, such situations would benefit from slower, more sustained release of the growth factor.  
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Different animal species — with variations in size and metabolism — might also require 
different release profiles of protein to best enhance bone formation.6   
 Release kinetics are difficult to monitor, particularly in vivo.  When delivered, the growth 
factors are subject to several biochemical factors that are not necessarily present in vitro.  For 
instance, bodily fluids, local proteins and enzymes, temperature, and pH can all affect the 
kinetics of release of rhBMP-2, as well as its subsequent bioactivity.2 
  
Protein dosage/concentration:  
 As suggested above, due to the inconsistent release profiles of rhBMPs, when used 
clinically, they are often delivered in supraphysiologic doses.  This ensures that a critical 
threshold of protein is isolated at the implant site and is maintained there for a sufficient period 
of time — this is, after all, the main role of growth factor delivery systems.2  Delivery systems 
that have the capacity to control protein release have the potential to decrease the overall dose of 
BMP necessary for bone regeneration at a defect site.10  Studies have indicated that by 
implementing a long-term, slow release delivery system, therapeutic results are enhanced, 
compared to a similar dose administered via short-term delivery.10, 23  A lower dose of BMP 
would lead to not only decreased overall cost, but also potentially fewer adverse side effects 
from the delivery of excessive amounts of the growth factor.   
Delivery systems for rhBMP-2:  
 With the aforementioned attributes as guidelines, many attempts have been made to 
engineer delivery systems for the optimal, sustained-release delivery of rhBMP-2.  In this 
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section, we briefly review of some of the material types and attempts that have been made for the 
sustained delivery of rhBMP-2.  There are four major categories of materials that have been 
examined for their use in drug delivery, each with their own associated advantages and 
disadvantages.2, 4, 6  They include natural polymers, inorganic materials, synthetic polymers, and 
composites of these. 
1) Natural polymers: 
 This category includes materials such as collagen (sponges, gels, demineralized bone 
matrix, or films), fibrin, chitosan, or hyaluronic acid.  Due to their animal sources, they tend to be 
biocompatible and naturally resorbable, and have the potential to naturally bind to certain growth 
factors.6  There are, however, potential issues including lack of availability and sourcing, 
difficulty in sterilization, and the potential for disease transmission.24  Several studies have 
investigated the use of such materials in the delivery of rhBMP-2.19-21 
 As suggested above, it has been suggested that collagen sponges are effective at 
sequestering rhBMP-2 at the defect site.  A 1998 study conducted by Hollinger et al.21 compared 
various treatment modalities for critical sized defects in the radii of rabbits: autograft, collagen 
sponge alone, rhBMP-2 soaked collagen sponge, or no treatment.  They concluded that 
delivering rhBMP-2 with a collagen sponge produced indistinct results from the autograft group, 
and improved results compared to collagen alone or no treatment at all.  The study utilized a 
large, 35 ug, dose of rhBMP-2 for the defect repair.21  A review of the use of collagen sponges 
for the delivery of rhBMP-2 references several similar studies that conclude that rhBMP-2 
delivered in a collagen carrier can be efficacious in bone formation.20  The authors note that 
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collagen sponges have the ability to elevate local levels of the protein at the defect site, 
compared to rhBMP-2 delivered alone in a liquid buffer.  Yet it is noted that estimates illustrate 
that 30% of the protein delivered in such collagen sponges is lost shortly after implantation.20  
Another group of investigators concluded that a gel combining heparin and chitosan for 
rhBMP-2 delivery in intramuscular injections in rats resulted in improved bone formation, when 
compared to rhBMP-2 implanted with type I collagen.19 
2) Inorganic materials: 
 Inorganic materials, such as calcium phosphate cements and ceramics, tend to have the 
structure most similar to that of bone.6, 24  Examples of such materials that have been used for 
rhBMP-2 carriers include hydroxyapatite (HAP) and beta tricalcium phosphate (β-TCP).  As they 
have a bone-like structure, they tend to be osteoconductive, providing a scaffold upon which 
bone formation can occur.  However, this structure can also render them brittle, with a limited 
potential for malleability.6  Porous HAP alone as a carrier for rhBMP-2 has illustrated limited 
potential for bone induction; partially, because the HAP itself does not resorb in a timely fashion.
25 
 With numerous advantages, β-TCP is promising for its use in the delivery of rhBMP-2.  
The ceramic material can be fabricated into three-dimensional scaffolds to fit defect sites; and its 
porous structure allows for the introduction of cells or other tissue-modifying factors.26, 27  In a 
study evaluating HAP versus β-TCP for the delivery of BMP-2, the β-TCP/BMP-2 system 
proved more effective at bone induction over a range of protein doses in a rat model.  Moreover, 
the authors noted that the retention of BMP-2 inside the scaffold was enhanced in the β-TCP 
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group compared to HAP/BMP-2 samples, suggesting an improved slow release delivery with the 
use of β-TCP.28 
  
3) Synthetic materials: 
 Unlike natural polymers, synthetic polymers do not require purification and do not pose a 
threat of disease transmission.  The most widely investigated material in this group are the 
poly(α-hydroxy acids), a class of synthetics composed of several polymers including 
poly(lactide) (PLA), poly(glycolide) (PLG), and the copolymer of these two monomers, 
poly(DL-lactide-co-glycolide) (PLGA).  Poly(α-hydroxy acids) are approved by the FDA, and 
are a common component of resorbable surgical sutures.29  Via hydrolysis, the polymers degrade 
into the component monomers.  Through various modes of processing, these synthetic materials 
can be formed into filaments, scaffolds, or microcapsules into which a growth factor, such as 
BMP-2, can be incorporated.10, 24, 30  RhBMP-2 is then released by diffusion through the polymer, 
or by polymer degradation;7 thus, providing slow, controlled growth factor release.  The greatest 
disadvantage of this group lies in the acidic byproducts released after hydrolysis.  The resultant 
decrease in pH has the potential to alter normal wound healing; and if the byproducts are not 
efficiently cleared, an inflammatory response can result.6   
 Poly(α-hydroxy acids) have been implicated for the the sustained delivery of BMP-2 and 
other growth factors.10, 31, 32  A 2010 study conducted by La et al.10 compared short-term versus 
long-term delivery of BMP-2 in mouse clavarial defects over a range of doses from 0 ug to 3 ug.  
In the short term delivery group, BMP-2 was suspended in a fibrin gel, while the long-term 
delivery system consisted of heparin-conjugated PLGA nanospheres suspended in a fibrin gel 
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that was loaded with BMP-2.  Electrostatic interactions between BMP-2 and heparin helped to 
maintain a local concentration of growth factor as well as control its slow release.  The authors 
concluded that long term delivery, with the incorporation of heparin-conjugated PLGA 
nanospheres, resulted in enhanced ossification at a lower dose of BMP-2 compared to the short-
term delivery samples.10  This study, among others,10, 31, 32 illustrates the successful delivery of 
BMP-2 at a sustained rate, utilizing a PLGA carrier.   
4) Composites: 
 Lastly, it has been the aim of some to attempt to combine components from the above 
groups in order to harness the advantages brought about by each material alone.   
  
 In the current paper, we discuss the delivery of rhBMP-2 in PLGA microcapsules.  
Microcapsules have the ability to provide sustained, slow release of proteins, growth factors, or 
drugs.7, 33  The goal of our work is to investigate a slow release delivery of the growth factor, 
with the hope of limiting the aforementioned side effect profile of rhBMP-2, and improving 
BMP-derived bone formation.  Previous work has concluded that rhBMP-2, encapsulated in 
PLGA microspheres, is efficacious for the sustained delivery of the protein.23, 32-34  In particular, 
work from our laboratory has evaluated the use of rhBMP-2/PLGA microcapsules in two in vivo 
models.  Wink et al.23 compared the delivery of rhBMP-2/PLGA microspheres and free rhBMP-2 
in subcutaneous injection implants in mice.  It was concluded that the sustained delivery of 
rhBMP-2 with PLGA microspheres reduced the effective dose of the growth factor required for 
ectopic ossification.  In a subsequent experiment, the same rhBMP-2/PLGA microcapsules were 
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investigated for the repair of a critical sized cranial defect in a rabbit model.35  Treatment groups 
consisted of no implant for repair, an empty collagen scaffold, a collagen scaffold loaded with 
free rhBMP-2, or a collagen scaffold loaded with rhBMP-2/PLGA microcapsules.  Again, the 
authors were able to conclude that the delivery of rhBMP-2/PLGA microcapsules resulted in 
improved bone formation, with greater volume and surface area, and effectively lowered the dose 
of rhBMP-2 required for bone formation, compared to other groups.35  
 The subject of protein encapsulation for the application or drug or growth factor delivery 
has been an area of extensive investigation.  Typically, encapsulation occurs through the 
formation of emulsions.  An emulsion results from the combination of two or more immiscible 
liquids that, due to their hydrophobic properties, create small, individual droplets.36  Emulsions 
can be oil-in-water (o/w), water-in-oil (w/o), or a combination of the above.  In the case of PLGA 
microcapsules, a water in oil in water (w/o/w) double emulsion is created to encapsulate 
rhBMP-2 in a PLGA shell.36  Conventionally, as in the studies described above, proteins have 
been encapsulated for delivery using a solvent extraction/evaporation method to create the 
double emulsion, resulting in a poly-disperse microcapsule sample.34, 37  Additionally, when 
proteins are encapsulated in such a manner, protein can capsulation efficiency is low, with often 
excessive protein loss.38, 39 
 Attempts have been made to improve upon the conventional encapsulation method, 
particularly by the application of microfluidics.23, 36, 40  Microfluidics involves the generation of 
one microcapsule at a time using a glass capillary device, thus producing monodisperse particles 
similar in size and shape, each fabricated in an identical fashion.36, 41, 42  The emulsions are 
created when a hydrophobic inner phase, containing a protein for encapsulation, is combined 
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with a hydrophobic middle phase (PLGA), all within a hydrophilic outer phase.  When the 
solvent from the middle phase evaporates, monodisperse microcapsules result.41  When proteins 
are encapsulated, there is virtually no loss of the inner layer protein.36, 43  
  
Scaffolds for rhBMP-2 delivery: 
 As noted above, ideal bone graft materials are malleable and have the ability to maintain 
the shape of the defect site.  For this reason, scaffold apparatuses are a key component in bone 
tissue engineering — providing an osteoconductive component.  Such materials provide an 
artificial matrix around which bone formation can occur.26, 44  Scaffolds not only provide a 
physical framework, but also encourage the proliferation and differentiation of tissue-forming 
cells; therefore, they are typically porous with a rough surface in order to encourage cell 
attachment.26  Three-dimensional pores throughout a scaffold allow for blood vessel infiltration, 
and the subsequent ingrown of new cells, nutrients, and tissues.45  Sharaf et al.46 describe the 
application of 3D printed poly(ε-caprolactone)(PCL) and beta tricalcium phosphate (β-TCP) 
scaffolds for their use in bone tissue engineering.  In an in vitro study, they concluded that PCL/
β-TCP scaffolds with smaller pore sizes produced increased infiltration and proliferation of bone 
marrow-derived progenitor cells, and enhanced new collagenous tissue formation.46 
Conclusion 
 The application of rhBMP-2 for bone tissue engineering holds great promise for 
researchers and clinicians in both the medical and dental fields.  It has clearly been demonstrated 
that the sustained, long-term release of the proteins can lead to improved ossification, owing 
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particularly to the rapid metabolism of the biologically active growth factor when it is delivered 
alone in solution.  Clinically, however, extreme, supraphysiologic doses of the protein are still 
being delivered to patients regularly, leading to instances of erratic, ectopic bone formation, and 
even life-threatening side effects.  Delivery systems for rhBMP-2 have been investigated 
extensively; yet still, further exploration into the best means of protein delivery — in order to 
curb the side effect profile and improve the quality of the bone generated — is warranted.   
!15
References 
1. Desilets CP, Marden LJ, Patterson AL, Hollinger JO. Development of synthetic bone-repair 
materials for craniofacial reconstruction. J Craniofac Surg. 1990;1(3):150-3. 
2. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins 
for bone regeneration and repair. Part A: Current challenges in BMP delivery. Biotechnol 
Lett. 2009;31(12):1817-24. 
3. Deatherage J. Bone materials available for alveolar grafting. Oral Maxillofac Surg Clin North 
Am. 2010;22(3):347-52, v. 
4. Bessa PC, Casal M, Reis RL. Bone morphogenetic proteins in tissue engineering: the road 
from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med. 2008;2(1):
1-13. 
5. Carreira AC, Lojudice FH, Halcsik E, Navarro RD, Sogayar MC, Granjeiro JM. Bone 
morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res. 2014;93(4):
335-45. 
6. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends 
Biotechnol. 2001;19(7):255-65. 
7. Chen RR, Mooney DJ. Polymeric growth factor delivery strategies for tissue engineering. 
Pharm Res. 2003;20(8):1103-12. 
8. Garrett MP, Kakarla UK, Porter RW, Sonntag VK. Formation of painful seroma and edema 
after the use of recombinant human bone morphogenetic protein-2 in posterolateral lumbar 
spine fusions. Neurosurgery. 2010;66(6):1044-9; discussion 9. 
9. Woo EJ. Adverse events after recombinant human BMP2 in nonspinal orthopaedic 
procedures. Clin Orthop Relat Res. 2013;471(5):1707-11. 
10. La WG, Kang SW, Yang HS, Bhang SH, Lee SH, Park JH, et al. The efficacy of bone 
morphogenetic protein-2 depends on its mode of delivery. Artif Organs. 2010;34(12):1150-3. 
11. McKay B. Local sustained delivery of recombinant human bone morphogenetic protein-2 
(rhBMP-2). Conf Proc IEEE Eng Med Biol Soc. 2009;2009:236-7. 
12. Schmidmaier G, Schwabe P, Strobel C, Wildemann B. Carrier systems and application of 
growth factors in orthopaedics. Injury. 2008;39 Suppl 2:S37-43. 
13. Haidar ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins 
for bone regeneration and repair. Part B: Delivery systems for BMPs in orthopaedic and 
craniofacial tissue engineering. Biotechnol Lett. 2009;31(12):1825-35. 
14. Cahill KS, Chi JH, Day A, Claus EB. Prevalence, complications, and hospital charges 
associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 
2009;302(1):58-66. 
15. Shah MM, Smyth MD, Woo AS. Adverse facial edema associated with off-label use of 
recombinant human bone morphogenetic protein-2 in cranial reconstruction for 
craniosynostosis. Case report. J Neurosurg Pediatr. 2008;1(3):255-7. 
!16
16. Alonso N, Tanikawa DY, Freitas Rda S, Canan L, Jr., Ozawa TO, Rocha DL. Evaluation of 
maxillary alveolar reconstruction using a resorbable collagen sponge with recombinant 
human bone morphogenetic protein-2 in cleft lip and palate patients. Tissue Eng Part C 
Methods. 2010;16(5):1183-9. 
17. Kao DW, Kubota A, Nevins M, Fiorellini JP. The negative effect of combining rhBMP-2 and 
Bio-Oss on bone formation for maxillary sinus augmentation. Int J Periodontics Restorative 
Dent. 2012;32(1):61-7. 
18. Fiorellini JP, Howell TH, Cochran D, Malmquist J, Lilly LC, Spagnoli D, et al. Randomized 
study evaluating recombinant human bone morphogenetic protein-2 for extraction socket 
augmentation. J Periodontol. 2005;76(4):605-13. 
19. Engstrand T, Veltheim R, Arnander C, Docherty-Skogh AC, Westermark A, Ohlsson C, et al. 
A novel biodegradable delivery system for bone morphogenetic protein-2. Plast Reconstr 
Surg. 2008;121(6):1920-8. 
20. Geiger M, Li RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv 
Drug Deliv Rev. 2003;55(12):1613-29. 
21. Hollinger JO, Schmitt JM, Buck DC, Shannon R, Joh SP, Zegzula HD, et al. Recombinant 
human bone morphogenetic protein-2 and collagen for bone regeneration. J Biomed Mater 
Res. 1998;43(4):356-64. 
22. Li B, Yoshii T, Hafeman AE, Nyman JS, Wenke JC, Guelcher SA. The effects of rhBMP-2 
released from biodegradable polyurethane/microsphere composite scaffolds on new bone 
formation in rat femora. Biomaterials. 2009;30(35):6768-79. 
23. Wink JD. Regenerating Bone in the Craniofacial Skeleton: Application of PLGA 
Microspheres for Recombinant Human Bone Morphogenetic Protein 2 Delivery. 
Philadelphia, PA: University of Pennsylvania; 2014. 
24. Seeherman H, Wozney JM. Delivery of bone morphogenetic proteins for orthopedic tissue 
regeneration. Cytokine Growth Factor Rev. 2005;16(3):329-45. 
25. Noshi T, Yoshikawa T, Dohi Y, Ikeuchi M, Horiuchi K, Ichijima K, et al. Recombinant 
human bone morphogenetic protein-2 potentiates the in vivo osteogenic ability of marrow/
hydroxyapatite composites. Artif Organs. 2001;25(3):201-8. 
26. Dorozhkin SV. Bioceramics of calcium orthophosphates. Biomaterials. 2010;31(7):1465-85. 
27. Bose S, Tarafder S. Calcium phosphate ceramic systems in growth factor and drug delivery 
for bone tissue engineering: a review. Acta Biomater. 2012;8(4):1401-21. 
28. Tazaki J, Murata M, Akazawa T, Yamamoto M, Ito K, Arisue M, et al. BMP-2 release and 
dose-response studies in hydroxyapatite and beta-tricalcium phosphate. Biomed Mater Eng. 
2009;19(2-3):141-6. 
29. Saito N, Murakami N, Takahashi J, Horiuchi H, Ota H, Kato H, et al. Synthetic 
biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv 
Drug Deliv Rev. 2005;57(7):1037-48. 
!17
30. Gentile P, Chiono V, Carmagnola I, Hatton PV. An overview of poly(lactic-co-glycolic) acid 
(PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15(3):3640-59. 
31. Lim TY, Poh CK, Wang W. Poly (lactic-co-glycolic acid) as a controlled release delivery 
device. J Mater Sci Mater Med. 2009;20(8):1669-75. 
32. Kirby GT, White LJ, Rahman CV, Cox HC, Qutachi O, Rose FR, et al. PLGA-Based 
Microparticles for the Sustained Release of BMP-2. Polymers. 2011;3:571-86. 
33. Isobe M, Yamazaki Y, Mori M, Ishihara K, Nakabayashi N, Amagasa T. The role of 
recombinant human bone morphogenetic protein-2 in PLGA capsules at an extraskeletal site 
of the rat. J Biomed Mater Res. 1999;45(1):36-41. 
34. Isobe M, Yamazaki Y, Oida S, Ishihara K, Nakabayashi N, Amagasa T. Bone morphogenetic 
protein encapsulated with a biodegradable and biocompatible polymer. J Biomed Mater Res. 
1996;32:433-8. 
35. Wink JD, Gerety PA, Sherif RD, Lim Y, Clarke NA, Rajapakse CS, et al. Sustained delivery 
of rhBMP-2 by means of poly(lactic-co-glycolic acid) microspheres: cranial bone 
regeneration without heterotopic ossification or craniosynostosis. Plast Reconstr Surg. 
2014;134(1):51-9. 
36. Shah RK, et al. Designer Emulsions Using Microfluidics. Materials Today. 2008;11:18-27. 
37. Borselli C, Ungaro F, Oliviero O, d'Angelo I, Quaglia F, La Rotonda MI, et al. Bioactivation 
of collagen matrices through sustained VEGF release from PLGA microspheres. J Biomed 
Mater Res A. 2010;92(1):94-102. 
38. Nihant N, Schugens C, Grandfils C, Jerome R, Teyssie P. Polylactide microparticles prepared 
by double emulsion/evaporation technique. I. Effect of primary emulsion stability. Pharm 
Res. 1994;11(10):1479-84. 
39. Yeo Y, Park K. Control of encapsulation efficiency and initial burst in polymeric 
microparticle systems. Arch Pharm Res. 2004;27(1):1-12. 
40. Lee M, Lee EY, Lee D, Park BJ. Stabilization and fabrication of microbubbles: applications 
for medical purposes and functional materials. Soft Matter. 2015;11(11):2067-79. 
41. Utada AS, Lorenceau E, Link DR, Kaplan PD, Stone HA, Weitz DA. Monodisperse double 
emulsions generated from a microcapillary device. Science. 2005;308(5721):537-41. 
42. Xu S, Nie Z, Seo M, Lewis P, Kumacheva E, Stone HA, et al. Generation of monodisperse 
particles by using microfluidics: control over size, shape, and composition. Angew Chem Int 
Ed Engl. 2005;44(5):724-8. 
43. Pessi J, Santos HA, Miroshnyk I, JoukoYliruusi, Weitz DA, Mirza S. Microfluidics-assisted 
engineering of polymeric microcapsules with high encapsulation efficiency for protein drug 
delivery. Int J Pharm. 2014;472(1-2):82-7. 
44. Hadlock TA, Vacanti JP, Cheney ML. Tissue engineering in facial plastic and reconstructive 
surgery. Facial Plast Surg. 1998;14(3):197-203. 
45. Lovett M, Lee K, Edwards A, Kaplan DL. Vascularization strategies for tissue engineering. 
Tissue Eng Part B Rev. 2009;15(3):353-70. 
!18
46. Sharaf B, Faris CB, Abukawa H, Susarla SM, Vacanti JP, Kaban LB, et al. Three-
dimensionally printed polycaprolactone and beta-tricalcium phosphate scaffolds for bone 
tissue engineering: an in vitro study. J Oral Maxillofac Surg. 2012;70(3):647-56. 
!19
